
Federal Trade Commission urged to investigate pharmacy benefit managers to uncover anticompetitive practices which raise drug prices for consumers

Joining other consumer organizations, PIRG submitted comments to the Federal Trade Commission (FTC) to recommend a broad investigation into the anticompetitive practices used by pharmacy benefit managers (PBMs). PBMS are the companies that manage the prescription drug portion of a health insurer’s benefits package. Our comments pointed out that “[i]n the past decade, PBM profits have more than doubled and increased to $28 billion annually.”
We urged the FTC to conduct a deep dive investigation into the PBM industry to “capture allegations of widespread fraudulent and deceptive practices.” Immediate attention by the FTC is necessary because the “PMB industry has avoided antitrust scrutiny for far too long.”
Photo Credit: Chris Potter on Flickr
See the Campaign

High Value Health Care
Topics
Updates

New Year’s resolutions to help you save money and avoid scams in 2024

Warning on eye drops expands: Now 27 brands and types could cause blindness

Insignia pressure cookers: Best Buy recalls nearly 1 million over burn risk

Slime Licker liquid candy recalled; 70 million products could be dangerous
